Polyclonal antibodies to xenogeneic endothelial cells induce apoptosis and block support of tumor growth in mice

Vaccine

Volumn 21, Issue 19-20, 2003, Pages 2667-2677

  Scappaticci, F A ^a   Contreras, A ^b   Boswell, C A ^c   Lewis, J S ^c   Nolan, G ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Antibodies; Apoptosis; Endothelial cells; Immunotherapy; Tumors

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; POLYCLONAL ANTIBODY; REAGENT;

ADENOCARCINOMA; ANGIOGENESIS; ANGIOSARCOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; COLORECTAL CARCINOMA; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG ACTIVITY; DRUG POTENCY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; MELANOMA CELL; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN FUNCTION; RABBIT; TUMOR GROWTH;

EID: 0038752102     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00693-X     Document Type: Article

References (35)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1(1):1995;27-31.
2. Boehm T., Folkman J., Browder T.et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 390(6658):1997;404-407.
3. Brooks P.C., Clark R.A., Cheresh D.A. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science. 264(5158):1994;569-571.
4. Ferrara N., Davis-Smyth T. The biology of vascular endothelial growth factor. Endocrinol. Rev. 18(1):1997;4-25.
5. St. Croix B., Rago C., Velculescu V.et al. Genes expressed in human tumor endothelium. Science. 289(5482):2000;1197-1202.
6. Fong T.A., Shawver L.K., Sun L.et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 59(1):1999;99-106.
7. Arap W., Pasqualini R., Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 279(5349):1998;377-380.
8. Folkman J. Antiangiogenic gene therapy. PNAS. 95(16):1998;9064-9066.
9. Scappaticci F.A., Smith R., Pathak A.et al. Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice. Mol. Ther. 3(2):2001;186-196.
10. Bergers G., Javaherian K., Lo K.M.et al. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science. 284(5415):1999;808-812.
11. Yokoyama Y., Dhanabal M., Griffioen A.W.et al. Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth. Cancer Res. 60(8):2000;2190-2196.
12. Browder T., Butterfield C.E., Kraling B.M.et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60(7):2000;1878-1886.
13. Klement G., Baruchel S., Rak J.et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105(8):2000;R15-R24.
14. Burrows F.J., Thorpe P.E. Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. PNAS. 90(19):1993;8996-9000.
15. Wei Y., Wang Q., Zhao X.et al. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat. Med. 6(10):2000;1160-1166.
16. Kinsella T.M., Nolan G.P. Episomal vectors rapidly and stably produce high-titer recombinant retrovirus. Hum. Gene. Ther. 7(12):1996;1405-1413.
17. Carmichael J., DeGraff W.G., Gazdar A.F.et al. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 47(4):1987;936-942.
18. Dixelius J., Larsson H., Sasaki T.et al. Endostatin-induced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis. Blood. 95(11):2000;3403-3411.
19. Williams L.E., Lewis M.R., Bebb G.G.et al. Biodistribution of 111In- and 90Y-labeled DOTA and maleimidocysteineamido-DOTA conjugated to chimeric anticarcinoembryonic antigen antibody in xenograft-bearing nude mice: comparison of stable and chemically labile linker systems. Bioconj. Chem. 9(1):1998;87-93.
20. Anderson C.J., Connett J.M., Schwartz S.W., Rocque P.A., Guo L.W., Philpott G.W.et al. Copper-64-labeled antibodies for PET imaging. J. Nucl. Med. 33(9):1992;1685-1691.
21. O'Reilly M.S., Boehm T., Shing Y.et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 88(2):1997;277-285.
22. Riccioni T., Cirielli C., Wang X.et al. Adenovirus-mediated wild-type p53 overexpression inhibits endothelial cell differentiation in vitro and angiogenesis in vivo. Gene Ther. 5(6):1998;747-754.
23. Eatock M.M., Schatzlein A., Kaye S.B. Tumour vasculature as a target for anticancer therapy. Cancer Treat. Rev. 26(3):2000;191-204.
24. Yamaguchi N., Anand-Apte B., Lee M.et al. Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J. 18(16):1999;4414-4423.
25. Kim Y.M., Jang J.W., Lee O.H.et al. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res. 60(19):2000;5410-5413.
26. Folkman J. Antiangiogenic therapy. In: Devita VT, Hellman S, Rosenberg SA, editors. Principles and practice of oncology. Philadelphia: Lippincott-Raven; 1997. p. 3075-85.
27. Sasaki T., Larsson H., Kreuger J.et al. Structural basis and potential role of heparin/heparan sulfate binding to the angiogenesis inhibitor endostatin. EMBO J. 18(22):1999;6240-6248.
28. Kaminski M.S., Zasadny K.R., Francis I.R.et al. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N. Engl. J. Med. 329(7):1993;459-465.
29. Witzig T.E., White C.A., Wiseman G.A.et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 17(12):1999;3793-3803.
30. Order S.E., Stillwagon G.B., Klein J.L.et al. Iodine 131 antiferritin, a new treatment modality in hepatoma: a Radiation Therapy Oncology Group study. J. Clin. Oncol. 3(12):1985;1573-1582.
31. Lenhard R.E., Order S.E., Spunberg J.J.et al. Isotopic immunoglobulin: a new systemic therapy for advanced Hodgkin's disease. J. Clin. Oncol. 3(10):1985;1296-1300.
32. Vriesendorp H.M., Herpst J.M., Leichner P.K.et al. Polyclonal Yttrium-90 labeled antiferritin for refractory Hodgkin's disease. Int. J. Radiat. Oncol. Biol. Phys. 17(4):1989;815-821.
33. Vriesendorp H.M., Herpst J.M., Germack M.A.et al. Phase I-II studies of Yttrium-labeled antiferritin treatment for end- stage Hodgkin's disease, including Radiation Therapy Oncology Group 87-01. J. Clin. Oncol. 9(6):1991;918-928.
34. Bergsland E., Hurwitz H., Fehrenbacher L., Meropol N.J., Novotny W.F., Gaudreault J.et al. A randomized phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus 5-fluorouracil/leucovorin (FU/LV) to FU/LV alone in patients with metastatic colorectal cancer. Proc. ASCO. 19:2000;242a.
35. DeVore R.F., Fehrenbacher L., Herbst R.S., Langer C.J., Kelly K., Gaudreault J.et al. A randomized phase II trial comparing rhumAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIb/IV NSCLC. Proc. ASCO. 19:2000;485a.0.